A more accurate diagnosis of Cushing's syndrome news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi). The results showed a significant reduction of albuminuria, a marker of kidney damage,2 by up to 39.5% when BI 690517 was given on top of empagliflozin, a sodium glucose ...
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor,...
Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Obesity rates in the US have skyrocketed, and so has the prevalence of several comorbid gastrointestinal and hepatic diseases - not all patients know their risks or have the financial means to take preventative measures.